{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:54:06Z","timestamp":1790927646962,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Transfusion\u2010dependent beta\u2010thalassemia is a chronic hematologic disorder necessitating lifelong blood transfusions and iron chelation therapy, which can lead to systemic and ocular complications. This study aimed to assess the frequency and characteristics of ocular complications in beta\u2010thalassemia patients treated with deferasirox.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross\u2010sectional study, 75 patients with transfusion\u2010dependent beta\u2010thalassemia receiving deferasirox for at least 1 year were evaluated. Demographic and clinical characteristics, including hemoglobin (Hb) and ferritin levels over 6 months, were collected. Comprehensive ophthalmological assessments included best corrected visual acuity (BCVA), refraction, slit\u2010lamp, fundus examination, optical coherence tomography (OCT), and fundus autofluorescence (FAF). Data were analyzed using SPSS version 26, and the significance level was set at 0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of the 75 patients was 27.8\u2009\u00b1\u20098.3 years, and 69.3% were female. The mean duration of deferasirox treatment was 53.6\u2009\u00b1\u200933.3 months at a daily dose of 24.1\u2009\u00b1\u20097.99\u2009mg\/kg. Mean Hb and ferritin levels were 8.99\u2009\u00b1\u20092.12\u2009g\/dL and 1419.8\u2009\u00b1\u20091218.6\u2009ng\/mL, respectively. Cataracts were identified in 7 of 75 patients (9.3%), with bilateral involvement in all affected patients. Ophthalmologic measurements were analyzed separately for each eye. BCVA showed a positive correlation with Hb in the right eye (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u2009=\u20090.460,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Mean myopic refractive errors were \u22120.95 D in the right eye and \u22120.83 D in the left eye. With\u2010the\u2010rule astigmatism was the most frequent subtype, accounting for 68% of evaluated eyes. FAF, performed in 43 patients, identified angioid streaks and hyperautofluorescent changes. A significant association was observed between cylindrical refractive error and treatment duration in the left eye (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010), and between cylindrical refractive error and daily deferasirox dose in the right eye (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ocular abnormalities were observed in patients with transfusion\u2010dependent beta\u2010thalassemia receiving deferasirox therapy. Longitudinal controlled studies are required to clarify the contribution of deferasirox to these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.73053","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:29:59Z","timestamp":1786951799000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ocular Complications in Patients With Transfusion\u2010Dependent Beta\u2010Thalassemia Receiving Deferasirox: A Cross\u2010Sectional Study"],"prefix":"10.1002","volume":"9","author":[{"given":"Abdolreza","family":"Medghalchi","sequence":"first","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital Guilan University of Medical Sciences Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh Rajabzadeh","family":"Kanafi","sequence":"additional","affiliation":[{"name":"Pediatric Diseases Research Center Guilan University of Medical Sciences Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital Guilan University of Medical Sciences Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Baghersalimi","sequence":"additional","affiliation":[{"name":"Pediatric Diseases Research Center Guilan University of Medical Sciences Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Doorandish","sequence":"additional","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital Guilan University of Medical Sciences Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afagh","family":"Hassanzadeh Rad","sequence":"additional","affiliation":[{"name":"Pediatric Diseases Research Center Guilan University of Medical Sciences Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shila","family":"Kianmehr","sequence":"additional","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital Guilan University of Medical Sciences Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6100-6332","authenticated-orcid":false,"given":"Bahram","family":"Darbandi","sequence":"additional","affiliation":[{"name":"Pediatric Diseases Research Center Guilan University of Medical Sciences Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/thalassrep14040010"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101138"},{"key":"e_1_2_13_4_1","first-page":"229","article-title":"Visual and Auditory Complications During Deferasirox Therapy in Beta\u2010Thalassemia","volume":"12","author":"Poosheshdoost P.","year":"2022","journal-title":"Iranian Journal of Pediatric Hematology and Oncology"},{"issue":"1","key":"e_1_2_13_5_1","article-title":"Deferasirox: Over a Decade of Experience in Thalassemia","volume":"10","author":"Moukalled N. M.","year":"2018","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18801"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1977116"},{"issue":"2","key":"e_1_2_13_8_1","first-page":"79","article-title":"Ocular Manifestations in Patients With Transfusion\u2010Dependent \u03b2\u2010Thalassemia","volume":"25","author":"Akritidou F.","year":"2021","journal-title":"Hippokratia"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82218"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0285-2"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001293"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S300974"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.08.005"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02490-z"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-019-01189-3"},{"issue":"7","key":"e_1_2_13_16_1","first-page":"514","article-title":"The Assessment of the Incidences of Ocular Toxicity and Ocular Findings Caused by Iron\u2010Chelating Compound","volume":"41","author":"Althanoon Z. A.","year":"2022","journal-title":"Arch Venez Farmacol y Ter"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-021-02030-1"},{"issue":"1","key":"e_1_2_13_18_1","first-page":"e03","article-title":"Lens Opacity as a Serious Side Effect Following Chelation Therapy in Beta Thalassemia: A Comparison Between Deferoxamine and Deferasirox; Randomized Double\u2010Blinded Clinical Trial","volume":"4","author":"Golpayegani M. R.","year":"2019","journal-title":"Journal of Preventive Epidemiology"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.5935\/0004-2749.20170082"},{"key":"e_1_2_13_20_1","volume-title":"Snellen Chart","author":"Azzam D.","year":"2025"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-022-00162-2"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-16638-0_3"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-016-0035-x"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13602"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3650-9"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.optom.2018.01.002"},{"key":"e_1_2_13_27_1","first-page":"101","article-title":"Deferasirox: Appraisal of Safety and Efficacy in Long\u2010Term Therapy","volume":"4","author":"Chaudhary P.","year":"2013","journal-title":"Journal of Blood Medicine"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2024.100495"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01647-y"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.61186\/hsm.3.4.292"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2021.1887900"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6207"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040109"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.170986"},{"issue":"1","key":"e_1_2_13_35_1","first-page":"55","article-title":"Comparison of the Heart and Liver Iron Deposition Status in Major \u03b2 Thalassemia Patients Treated With Two Iron Chelation Drugs of \u201cDeferoxamine and Deferasiroxon\u201d Using MRI T2* Technique","volume":"12","author":"Moradveisi","year":"2015","journal-title":"Scientific Journal of Iran Blood Transfusion Organization"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-7896-6_28"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.2478\/amb-2024-0048"},{"key":"e_1_2_13_38_1","unstructured":"C. H.PrasadandY. M.Prasad \u201cStudy of Ocular Manifestations among Beta Thalassemia Major Patients\u201d The Virtual Health Library (VHL). Prasad C. Harihara; Prasad Y. M. Satyanarayana. IMSEAR. 2019."},{"issue":"10","key":"e_1_2_13_39_1","first-page":"603","article-title":"Comparison of Ocular Characteristic Between Major Thalassemia and Healthy Group","volume":"59","author":"Koochakzadeh L.","year":"2021","journal-title":"Acta Medica Iranica"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.62276\/OphthalmolPak.14.03.152"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-11"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/thalassrep13030017"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040112"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2023.11.24"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.2174\/18743641-v16-e221115-2022-13"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007476.pub3"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.73053","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.73053","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.73053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:14:06Z","timestamp":1790925246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.73053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/hsr2.73053"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.73053","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e73053"}}